Evolving landscape of targeted immunotherapeutic interventions and CAR-T therapy for acute myeloid leukemia Authors: Tara Chand Yadav, Shanid Mohiyuddin, Gerhard C. Hildebrandt, Senthilnathan Palaniyandi Published: 2026 ABSTRACT Acute myeloid leukemia is an aggressive and heterogeneous disease characterized by abnormal proliferation of leukemic blast cells and niche remodeling. Traditional therapies fail to manage evolving and resistant AML subtypes. Next-generation immunotherapeutic interventions, such as CAR-T cells, immune checkpoint inhibitors, antibody-drug conjugates, and antibody-based therapeutics, target leukemic blast cells. This review aims to provide a comprehensive overview of the evolving landscapes of immunotherapeutic strategies, challenges, and breakthroughs in tackling AML. Introduction Acute myeloid leukemia (AML) is a physiologically complex and highly aggressive clonal hematopoietic stem-cell cancer leading to disruption of normal hematopoiesis, resulting in bone-marrow failure and death1. Malignant clonal expansion of myeloid progenitor stem cells is the hallmark of AML2. Aberrant genetic mutations/abnormalities, epigenetic alterations, irregular proliferations, and clonal expansion of hematopoietic stem cells (HSCs) give rise to leukemic stem cells. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the most common cellular therapeutic approaches for patients with acute myeloid leukemia (AML). The recognition of tumor antigens by donor immune cells, followed by the elimination of leukemia, is called graft-versus-leukemia (GVL)3 and cytoreduction by conditioning regime offers curative potential for the allo-HSCT. But because of shared alloantigen recognition, the clinical translation of GVL after allo-HSCT is often limited by the risk of graft-versus-host disease (GVHD). In AML subtypes, allo-HSCT provides the most durable, potentially curative cure through a robust GVL response. However, the curative potential of allo-HSCT centers depends on donor matching, optimizing recipient conditioning, and implementing GVHD prophylaxis that preserves GVL activity4. Leukemic stem cells (LSCs) are multipotent, self-renewing, and highly proliferative immature myeloid progenitor cells that drive uncontrolled proliferation, maintain AML blast cells, leading to bone marrow failure characterized by anemia, thrombocytopenia, and granulocytopenia2. LSCs are considered a rare drug-resistant population in AML that influences disease progression, maintenance, and relapse5. LSCs in AML regulate the leukemic blasts and exhibit enhanced self-renewal, quiescence, and chemoresistance, contributing to relapse6. LSC is very important in the context of GVL after allo-HSCT for therapy design, as GVL primarily reflects activity against LSCs. LSCs are commonly a CD34+/CD38− population of cells, but vary from patient to patient5. This heterogeneous phenotype of LSCs delimits the targeted therapeutic approach. Moreover, the leukemic microenvironment influences the quiescence and survival of LSCs, further reducing the therapeutic effectiveness7. GVL after allo-HSCT involves immune cells against residual leukemic cells, including LSCs. Effective GVL against LSCs is critical for remission and cure, but must be balanced against GVHD risk. Although LSCs’ targeting strategies show therapeutic promise, several challenges limit their effectiveness. The phenotypic and antigenic diversity of LSCs among AML subtypes restricts the therapeutic ability to recognize and eliminate LSCs. In addition, LSC antigens such as CD33 and CD123 are present on normal hematopoietic stem cells, which can lead to off-target toxicity and complicate their clinical application8. These side effects pinpoint the need to refine targeting approaches for LSCs by integrating patient-specific antigen profiles, combinatorial targeting strategies, and CAR-NK cell therapy to increase the efficacy whilst minimizing damage to normal stem cells. The pathogenesis becomes more complex due to somatic mutations in leukemia-associated antigens, which increase the risk of AML in older patients9. Leukemogenesis and disease heterogeneity, which impact diagnosis, prognosis, and therapy outcomes, are also influenced by genomic factors, chromatin structure, RNA splicing, and cell signaling pathways10. The bone marrow microenvironment (BMM), also referred to as the niche, serves as an ideal reservoir for leukemic cell proliferation and survival, thereby exacerbating the disease’s pathophysiology. BMM actively transforms normal HSCs into malignant leukemic blast cells and supports the survival of persistent leukemic stem cells through direct and indirect interactions with stromal cells, osteoblasts, osteoclasts, GM-CSF, E-selectins, VEGF/VEGFR, and by secreting growth factors, cytokines, and chemokines, rendering protection from cytotoxic agents, highlighting the unmet need for targeting this signaling crosstalk2,11. BMM acts as a “safe-haven” for circulating LSCs; chemotherapies become ineffective due to quiescent state, phenotypic plasticity, and their innate ability to evade apoptosis12,13. Despite significant advancement and progress in the understanding of AML pathophysiology, patient outcomes remain dismal and elusive, with low survival and high relapse, particularly in older geriatric patients14. Conventional AML therapies lack specificity, suffer from off-target toxicity, rapid drug metabolism/clearance, and incomplete LSCs eradication due to the immunosuppressive milieu of the leukemic niche5. These impediments can be circumvented by selective delivery of cytotoxic drugs/inhibitors at the target site, resulting in disruption of leukemic cells and niche microenvironment15. Several chemotherapeutic drugs, including Cytarabine, Azacitidine, Midostaurin, Enasidenib, Ivosidenib, and Glasdegib, have shown significant efficacy in depleting the LSC reservoir in clinical trials16. Nucleic acid-based therapeutics, such as small interfering RNAs (siRNAs), oligonucleotides, and aptamer-drug conjugates acting as differentiation agents, reduced AML leukemic blasts, but complete remission was suboptimal in preclinical and clinical investigations17. Table 1a, b comprises emerging differentiation therapies, chemotherapy, and oligonucleotide-based therapeutic modalities.Table 1(a): The list of therapeutic modalities of AML and their molecular mechanism in clinical trials. (b): The list of nucleotide/ oligonucleotide-based therapies and their mechanism of action in progression of AML therapeutics(a)Therapeutic AgentMechanism of actionDisease subtypeNCT numberRoute of deliveryFDA approvalRecommended dosageATRADegradation of rarα: PML fusion protein to restore retinoic acid signaling and differentiation or apoptosis in APL cellAPLNCT00151255OralPediatric/ adults APL with t (15;17) translocation or presence of PML/rarα22.5 mg/m2 twice dailyATOInduces apoptosis and promotes differentiation of APL cells. Affects glycolytic pathwayAPLNCT04996030IVAdults with low-risk APL (for remission)0.15 mg/kg dailyATRA+ ATOCombination therapy to target rarα: PML fusion catabolismAPLNCT02339740ATRA: OralATO: IVStandard/high risk pediatric APL (PML:rarα)ATRA: 12.5 mg/m2ATO: 0.15 mg/kgATRA, and ATO +/ - GOCombination therapy to target rarα: PML fusion catabolismAPLNCT01409161ATRA: OralATO: IVNewly diagnosed APLATRA:45 mg/m2, ATO 0.15 mg/kg daily. GO: 6-9 mg/m2MidostaurinInhibition of FLT3, KIT, VEGFR2, and PDGFR and reduction in TregsFLT3 mutated AMLNCT01883362OralNewly diagnosed FLT3 mutated AML50 mg twice dailyGilteritinibInhibition of FLT3 and downstream signaling, induce apoptosis, AXL inhibitionR/R AMLNCT02421939OralR/R FLT3 mutated AML120 mg dailyEnasidenibInhibition of mutant IDH2 enzymes, downregulation of 2-HG enzyme and induction of differentiation in cells.IDH2 R/R AMLNCT01915498OralR/R AML100 mg dailyIvosidenibInhibit mutant IDH1 and induce its related differentiation and apoptosis signalingIDH1 mutated AMLNCT03173248OralNewly diagnosed IDH1 AML500 mg dailyCrenolanibInhibiting FLT3 and PDGFR, cell growth, Anti-angiogenesis,FLT3 mutated AMLNCT01657682OralFast track designation for R/R FLT3 AML100 mg TIDGemtuzumab Ozogamicin (GO)Binding to CD33+ cancer cells, internalization and release of calicheamicin, lead to DNA damage and targeted cell killingR/R CD33+ AMLNCT03727750IVNewly diagnosed de novo CD33+ AML3 mg/m2CytarabineInterfering with DNA synthesis and repair and apoptosis induction in cancer cellsPediatric APLNCT01191541IVNewly diagnosed t-AML or AML-MRC100 mg/m2AlisertibInhibition of AURKA, Induction of cell cycle arrest and apoptosisHigh risk AMLNCT02560025OralUnder clinical trials for safety and efficacy30mg twice dailyAzacitidineDNA demethylation, Induction of Cell DeathAML, aged ≥55 yearsNCT01757535OralAML with cri300 mgDecitabineDemethylating agent, inhibiting DNMT enzymesAML, relapsed AMLNCT01687400IVNewly diagnosed AML20 mg/m2OlutasidenibInhibits mutated IDH1and Blocks oncometabolite productionR/R IDH1 mutated AMLNCT02719574OralR/R IDH1 AML150 mg twice dailyVenetoclax +azacitidine/ decitabine Combination therapy: Combination effect of Venetoclax and azacitidine/ decitabine (R/R) AMLNCT02203773Venetoclax: oral, Azacitidine:IVdecitabine: SCNewly diagnosed AMLVenetoclax: 400 mg Azacitidine:75 mg/m2, Decitabine: 20 mg/m2GlasdegibInhibition of Hh signaling, restricts growth, survival, and proliferation of cancer.AMLNCT03416179OralNewly diagnosed AML with comorbidities100 mgRevumenibMenin inhibition, downregulation of genes MEIS1, HOXA9, CDK6MT2A rearranged or NPM1 mutant leukemiaNCT04065399OralR/R AML with KMT2A translocation160 mg/m2Asciminiballosteric inhibitor of the BCR-ABL1 tyrosine kinase (TKI)Ph+ CMLNCT07354074OralPediatric Patients with Ph+ CML-CP80 mg dailyImatinibbinds to ATP-binding site of the BCR-ABL tyrosine kinase, preventing its activation (TKI)Ph+ CMLNCT00471497OralPatients With Ph+ CML-CP400 mg dailyNilotinibbinds to ATP-binding site of the BCR-ABL tyrosine kinase, preventing its activation (TKI)Ph+ CML in Chronic PhaseNCT00481052OralNewly diagnosed Ph+ CML-CP300 mgDasatinibInhibits BCR-ABL and SRC-family kinases, controlling leukemia (TKI)Ph+ CMLNCT00482703OralNewly diagnosed Ph+ CML-CP100 mg dailyPonatinibbinds to ATP-binding site of the native and mutated BCR-ABL1 tyrosine kinase (TKI)CP-CML ≤1%BCR:ABL1NCT01746836OralNewly diagnosed Ph+ CP- CML45 mg dailyBosutinibInhibits autophosphorylation of the BCR-ABL oncoprotein and SRC family kinases (TKI)Ph+ CMLNCT05363488OralNewly diagnosed Ph+ CML100 mg daily(b)Nucleic acid therapeuticsMechanism of actionDisease subtypeNCT noPrexigebersen (BP1001)Antisense oligonucleotide: inhibiting Grb2 protein synthesis, restricts cancer growth.High Risk R/R AMLNCT02781883.BP1002Antisense oligodeoxynucleotide inhibiting Bcl-2 synthesis, restricts cancer growth.R/R AMLNCT05190471G4460C-myb antisense oligonucleotide, binding to proto-oncogene CMYB and triggering rnase H-dependent degradation.Chronic myelogenous leukemia (CML)NCT00002592OblimersenAntisense oligonucleotide targets the first six codons of Bcl-2 mrna to form a DNA/RNA complex.R/R AMLNCT00004862AEG35156Selectively blocking the X-linked inhibitor of apoptosis protein (XIAP).R/R AMLNCT00363974AS1411G-rich DNA aptamer that targets the protein nucleolin, destabilize Bcl-2 mrna and reduce Bcl-2 protein synthesis, leading to cell death.R/R AMLNCT00512083CR1-02 / 5-FU-mir-15aMir-15a mimic (tumor-suppressive mirna; 5-fluorouracil conjugated, multiple targets.R/R AMLEudract 2021-006332-46Mirna-193b-3pTargeting MAPK/ERK cascade and decrease proliferation and induce cell cycle arrest.Pediatric AMLPre-clinicalPEI-LA/siflt3Target FLT-3 to suppression of proliferation in combination with FLT3 inhibitors.AMLPre-clinicalCPP44-p16mis-FFY-4RPeptide-daunorubicin-sirna conjugate, inhibits cyclin-dependent kinase 4/6 (CDK4/6) activity to induce G1-phase cell cycle arrest and sililrb4, to silence the LILRB4 geneAMLPre-clinicalBCL2L12 and survivin sirnaSilence BCL2L12 and survivin and decrease in proliferation of KG1 and stem-cell-like KG1a cellsAMLPre-clinicalAbbreviation used: ATRA All-Trans Retinoic Acid, R/R Relapsed/Refractory, rarα retinoic acid receptor α, PML promyelocytic leukemia, APL Acute Promyelocytic Leukemia, ATO Arsenic Trioxide, IV Intravenous, FLT3 Fms-like tyrosine kinase 3, t-AML therapy-related AML, MRC myelodysplasia-related changes, Cri incomplete blood count recovery, SC subcutaneous, KMT2A lysine methyltransferase 2A, Tregs T regulatory cells, DNMT DNA methyltransferase, AURKA Aurora kinase A, 2-HG 2-hydroxyglutarate, VEGFR2 vascular endothelial growth factor receptor 2, PDGFR platelet-derived growth factor receptor, IDH1 Isocitrate Dehydrogenase 1, IDH2 Isocitrate Dehydrogenase 2, Hh hedgehog, MEIS1 Myeloid Ecotropic Viral Integration Site 1, HOXA9 homeobox A9, CDK6 cyclin-dependent kinase 6, MT2A Metallothionein 2A, NPM1 Nucleophosmin 1, Ph+ CML Philadelphia chromosome-positive chronic myeloid leukemia, BCR Breakpoint Cluster Region, ABL1 Abelson murine leukemia viral oncogene homolog 1, TKI Tyrosine kinase inhibitors, CP chronic phase. Table 1(a): The list of therapeutic modalities of AML and their molecular mechanism in clinical trials. (b): The list of nucleotide/ oligonucleotide-based therapies and their mechanism of action in progression of AML therapeutics(a)Therapeutic AgentMechanism of actionDisease subtypeNCT numberRoute of deliveryFDA approvalRecommended dosageATRADegradation of rarα: PML fusion protein to restore retinoic acid signaling and differentiation or apoptosis in APL cellAPLNCT00151255OralPediatric/ adults APL with t (15;17) translocation or presence of PML/rarα22.5 mg/m2 twice dailyATOInduces apoptosis and promotes differentiation of APL cells. Affects glycolytic pathwayAPLNCT04996030IVAdults with low-risk APL (for remission)0.15 mg/kg dailyATRA+ ATOCombination therapy to target rarα: PML fusion catabolismAPLNCT02339740ATRA: OralATO: IVStandard/high risk pediatric APL (PML:rarα)ATRA: 12.5 mg/m2ATO: 0.15 mg/kgATRA, and ATO +/ - GOCombination therapy to target rarα: PML fusion catabolismAPLNCT01409161ATRA: OralATO: IVNewly diagnosed APLATRA:45 mg/m2, ATO 0.15 mg/kg daily. GO: 6-9 mg/m2MidostaurinInhibition of FLT3, KIT, VEGFR2, and PDGFR and reduction in TregsFLT3 mutated AMLNCT01883362OralNewly diagnosed FLT3 mutated AML50 mg twice dailyGilteritinibInhibition of FLT3 and downstream signaling, induce apoptosis, AXL inhibitionR/R AMLNCT02421939OralR/R FLT3 mutated AML120 mg dailyEnasidenibInhibition of mutant IDH2 enzymes, downregulation of 2-HG enzyme and induction of differentiation in cells.IDH2 R/R AMLNCT01915498OralR/R AML100 mg dailyIvosidenibInhibit mutant IDH1 and induce its related differentiation and apoptosis signalingIDH1 mutated AMLNCT03173248OralNewly diagnosed IDH1 AML500 mg dailyCrenolanibInhibiting FLT3 and PDGFR, cell growth, Anti-angiogenesis,FLT3 mutated AMLNCT01657682OralFast track designation for R/R FLT3 AML100 mg TIDGemtuzumab Ozogamicin (GO)Binding to CD33+ cancer cells, internalization and release of calicheamicin, lead to DNA damage and targeted cell killingR/R CD33+ AMLNCT03727750IVNewly diagnosed de novo CD33+ AML3 mg/m2CytarabineInterfering with DNA synthesis and repair and apoptosis induction in cancer cellsPediatric APLNCT01191541IVNewly diagnosed t-AML or AML-MRC100 mg/m2AlisertibInhibition of AURKA, Induction of cell cycle arrest and apoptosisHigh risk AMLNCT02560025OralUnder clinical trials for safety and efficacy30mg twice dailyAzacitidineDNA demethylation, Induction of Cell DeathAML, aged ≥55 yearsNCT01757535OralAML with cri300 mgDecitabineDemethylating agent, inhibiting DNMT enzymesAML, relapsed AMLNCT01687400IVNewly diagnosed AML20 mg/m2OlutasidenibInhibits mutated IDH1and Blocks oncometabolite productionR/R IDH1 mutated AMLNCT02719574OralR/R IDH1 AML150 mg twice dailyVenetoclax +azacitidine/ decitabine Combination therapy: Combination effect of Venetoclax and azacitidine/ decitabine (R/R) AMLNCT02203773Venetoclax: oral, Azacitidine:IVdecitabine: SCNewly diagnosed AMLVenetoclax: 400 mg Azacitidine:75 mg/m2, Decitabine: 20 mg/m2GlasdegibInhibition of Hh signaling, restricts growth, survival, and proliferation of cancer.AMLNCT03416179OralNewly diagnosed AML with comorbidities100 mgRevumenibMenin inhibition, downregulation of genes MEIS1, HOXA9, CDK6MT2A rearranged or NPM1 mutant leukemiaNCT04065399OralR/R AML with KMT2A translocation160 mg/m2Asciminiballosteric inhibitor of the BCR-ABL1 tyrosine kinase (TKI)Ph+ CMLNCT07354074OralPediatric Patients with Ph+ CML-CP80 mg dailyImatinibbinds to ATP-binding site of the BCR-ABL tyrosine kinase, preventing its activation (TKI)Ph+ CMLNCT00471497OralPatients With Ph+ CML-CP400 mg dailyNilotinibbinds to ATP-binding site of the BCR-ABL tyrosine kinase, preventing its activation (TKI)Ph+ CML in Chronic PhaseNCT00481052OralNewly diagnosed Ph+ CML-CP300 mgDasatinibInhibits BCR-ABL and SRC-family kinases, controlling leukemia (TKI)Ph+ CMLNCT00482703OralNewly diagnosed Ph+ CML-CP100 mg dailyPonatinibbinds to ATP-binding site of the native and mutated BCR-ABL1 tyrosine kinase (TKI)CP-CML ≤1%BCR:ABL1NCT01746836OralNewly diagnosed Ph+ CP- CML45 mg dailyBosutinibInhibits autophosphorylation of the BCR-ABL oncoprotein and SRC family kinases (TKI)Ph+ CMLNCT05363488OralNewly diagnosed Ph+ CML100 mg daily(b)Nucleic acid therapeuticsMechanism of actionDisease subtypeNCT noPrexigebersen (BP1001)Antisense oligonucleotide: inhibiting Grb2 protein synthesis, restricts cancer growth.High Risk R/R AMLNCT02781883.BP1002Antisense oligodeoxynucleotide inhibiting Bcl-2 synthesis, restricts cancer growth.R/R AMLNCT05190471G4460C-myb antisense oligonucleotide, binding to proto-oncogene CMYB and triggering rnase H-dependent degradation.Chronic myelogenous leukemia (CML)NCT00002592OblimersenAntisense oligonucleotide targets the first six codons of Bcl-2 mrna to form a DNA/RNA complex.R/R AMLNCT00004862AEG35156Selectively blocking the X-linked inhibitor of apoptosis protein (XIAP).R/R AMLNCT00363974AS1411G-rich DNA aptamer that targets the protein nucleolin, destabilize Bcl-2 mrna and reduce Bcl-2 protein synthesis, leading to cell death.R/R AMLNCT00512083CR1-02 / 5-FU-mir-15aMir-15a mimic (tumor-suppressive mirna; 5-fluorouracil conjugated, multiple targets.R/R AMLEudract 2021-006332-46Mirna-193b-3pTargeting MAPK/ERK cascade and decrease proliferation and induce cell cycle arrest.Pediatric AMLPre-clinicalPEI-LA/siflt3Target FLT-3 to suppression of proliferation in combination with FLT3 inhibitors.AMLPre-clinicalCPP44-p16mis-FFY-4RPeptide-daunorubicin-sirna conjugate, inhibits cyclin-dependent kinase 4/6 (CDK4/6) activity to induce G1-phase cell cycle arrest and sililrb4, to silence the LILRB4 geneAMLPre-clinicalBCL2L12 and survivin sirnaSilence BCL2L12 and survivin and decrease in proliferation of KG1 and stem-cell-like KG1a cellsAMLPre-clinicalAbbreviation used: ATRA All-Trans Retinoic Acid, R/R Relapsed/Refractory, rarα retinoic acid receptor α, PML promyelocytic leukemia, APL Acute Promyelocytic Leukemia, ATO Arsenic Trioxide, IV Intravenous, FLT3 Fms-like tyrosine kinase 3, t-AML therapy-related AML, MRC myelodysplasia-related changes, Cri incomplete blood count recovery, SC subcutaneous, KMT2A lysine methyltransferase 2A, Tregs T regulatory cells, DNMT DNA methyltransferase, AURKA Aurora kinase A, 2-HG 2-hydroxyglutarate, VEGFR2 vascular endothelial growth factor receptor 2, PDGFR platelet-derived growth factor receptor, IDH1 Isocitrate Dehydrogenase 1, IDH2 Isocitrate Dehydrogenase 2, Hh hedgehog, MEIS1 Myeloid Ecotropic Viral Integration Site 1, HOXA9 homeobox A9, CDK6 cyclin-dependent kinase 6, MT2A Metallothionein 2A, NPM1 Nucleophosmin 1, Ph+ CML Philadelphia chromosome-positive chronic myeloid leukemia, BCR Breakpoint Cluster Region, ABL1 Abelson murine leukemia viral oncogene homolog 1, TKI Tyrosine kinase inhibitors, CP chronic phase. (a): The list of therapeutic modalities of AML and their molecular mechanism in clinical trials. (b): The list of nucleotide/ oligonucleotide-based therapies and their mechanism of action in progression of AML therapeutics ATRA: Oral ATO: IV ATRA: 12.5 mg/m2 ATO: 0.15 mg/kg ATRA: Oral ATO: IV Venetoclax: oral, Azacitidine:IV decitabine: SC Abbreviation used: ATRA All-Trans Retinoic Acid, R/R Relapsed/Refractory, rarα retinoic acid receptor α, PML promyelocytic leukemia, APL Acute Promyelocytic Leukemia, ATO Arsenic Trioxide, IV Intravenous, FLT3 Fms-like tyrosine kinase 3, t-AML therapy-related AML, MRC myelodysplasia-related changes, Cri incomplete blood count recovery, SC subcutaneous, KMT2A lysine methyltransferase 2A, Tregs T regulatory cells, DNMT DNA methyltransferase, AURKA Aurora kinase A, 2-HG 2-hydroxyglutarate, VEGFR2 vascular endothelial growth factor receptor 2, PDGFR platelet-derived growth factor receptor, IDH1 Isocitrate Dehydrogenase 1, IDH2 Isocitrate Dehydrogenase 2, Hh hedgehog, MEIS1 Myeloid Ecotropic Viral Integration Site 1, HOXA9 homeobox A9, CDK6 cyclin-dependent kinase 6, MT2A Metallothionein 2A, NPM1 Nucleophosmin 1, Ph+ CML Philadelphia chromosome-positive chronic myeloid leukemia, BCR Breakpoint Cluster Region, ABL1 Abelson murine leukemia viral oncogene homolog 1, TKI Tyrosine kinase inhibitors, CP chronic phase. Emerging immunotherapies leverage the immune system’s ability to target and eradicate LSC, offering a ray of hope and preventing these limitations. Immunotherapeutic modalities, such as monoclonal antibodies (gemtuzumab ozogamicin-anti-CD33, Cusatuzumab-Anti-CD70), engineered antibodies (bi- and trispecific), and CAR-T cells and CAR-NK cellular therapies targeting CD123, CLL-1, and other leukemia-associated antigens, have shown promising anti-leukemic responses in relapsed/refractory cases that are progressing in clinical trials18,19. Furthermore, nano-immunotherapy and patient-specific, neo-antigen personalized anticancer vaccines that offer a multi-antigenic immune response are emerging as potential immunotherapies for the selective targeting and eradication of LSCs and the AML niche20,21. Fig. 1 illustrates various cellular, antibody, vaccine, oligonucleotide, immunotherapeutic, and other investigational chemotherapeutic modalities for the management of AML. The present review aims to provide a brief insight into current trends and challenges in immunotherapies and to explore immune surveillance evasion by AML cells, the intrinsic characteristics of leukemic blasts, and the immunosuppressive attributes of the bone marrow tumor microenvironment. It also outlines how current and emerging immunotherapeutic interventions intend to disrupt these evasion tactics and reinstate efficacious anti-leukemic effects. The emphasis is laid on the intricate relationship between AML cells and the bone marrow microenvironment, which plays a vital role in immune suppression and disease progression22.Fig. 1Graphical representation of an integrative overview of existing and emerging therapeutic modalities and strategies for AML.The illustration summarizes key treatment interventions arranged radially around the leukemic cell, including chemotherapy, differentiation therapy, cell-based therapies, antibody-based therapies, vaccines, targeted delivery using DNA/RNA, stem-cell-based therapy, biomimetic nanoparticles, and other investigational immunotherapeutic modalities for AML management. Graphical representation of an integrative overview of existing and emerging therapeutic modalities and strategies for AML. The illustration summarizes key treatment interventions arranged radially around the leukemic cell, including chemotherapy, differentiation therapy, cell-based therapies, antibody-based therapies, vaccines, targeted delivery using DNA/RNA, stem-cell-based therapy, biomimetic nanoparticles, and other investigational immunotherapeutic modalities for AML management. Leukemic stem cell modulation and immune evasion AML blast and leukemic stem cells (LSCs) engage distinctive intrinsic and extrinsic mechanisms to evade immune surveillance13. LSCs show self-renewal, chemotherapy-resistant subpopulation of AML cells having excellent epigenetic and phenotypic plasticity, and can escape immune detection using immunoediting approaches to reshape the tumor microenvironment. During immune escape, AML cells induce the proliferation of immunosuppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells, and anti-inflammatory macrophages, in the tumor microenvironment to sustain differentiation arrest16,23. These myeloid-derived suppressor cells inhibit the functionality of effector T and NK cells, inducing tolerance against leukemic antigens and leading to sustained leukemic growth and persistence. Additionally, blast cells secrete activating ligands and shed extracellular vesicles loaded with immunomodulatory molecules, thereby reconfiguring the microenvironment to their benefit24. The immune evasion mechanism comprises the following steps: (i) Downregulation of MHC and Decreased Antigen Presentation. The downregulation of the major histocompatibility complex (MHC), especially HLA class II, is a hallmark and central aspect of immune evasion in AML. The genetic and epigenetic alterations that are explicitly present after allogeneic hematopoietic stem cell transplantation (allo-HSCT) reduce leukemic cell antigen presentation, allowing them to evade T-cell recognition25. For instance, interferon gamma (IFN-γ) showed reversal of suppression, hence elaborating an epigenetic mechanism of immune-editing and downregulation of HLA/ MHC molecules resulting into the survival of immunodeficient leukemic clones which are responsible for relapses after transplantation26; (ii) Immune Checkpoint Activation and Overexpression of Inhibitory Ligands; AML blasts tend to overexpress inhibitory checkpoint receptors and their ligands, such as PD-L1, PD-L2, and CTLA-4, that have been associated with progression and poor prognosis. These molecules both directly inhibit effector T cell function, induce exhaustion, and create an immunosuppressive environment within the bone marrow. In addition, immune checkpoints are not limited to the T cell surface; AML blasts themselves have been shown to express these suppressive molecules, further facilitating immune escape27. (iii) Bone Marrow Niche Modulation; The bone marrow niche or microenvironment presents a haven that is being utilized by the AML blast cells to facilitate immune evasion. By cross-talk with stromal, endothelial, and mesenchymal cells, immune-mediated deletion is protected by the leukemic blasts28. These interactions lead to enhanced secretion of immunosuppressive cytokines and metabolites such as indoleamine 2,3-dioxygenase (IDO), arginase, reactive oxygen species (ROS), and galectin-9 that inhibit cytotoxic T lymphocytes and NK cells, induce the recruitment of regulatory T cells (Treg), and polarize macrophages to the suppressive M2 phenotype29,30; (iv) Leukemic stem-cell modulation; AML LSCs attain quiescence and stemness through an intricate landscape of signaling pathways. The key signaling pathways, such as the Wnt pathway, are crucial. Overexpression of FOXM1 stabilizes β-catenin, and in conjunction with high levels of lncRNA DANCR, it overexpresses MYC, thereby enhancing LSC latency31,32. Quiescent LSCs primarily arrest at the G0 cell-cycle stage, characterized by lower levels of ROS16. In addition to this, microRNA-126 (miR-126) also regulated the PI3K/AKT pathway strictly; miR-126 upregulation in endothelial cells preserves LSC dormancy via targeted downregulation of CDK3, rendering them resistant to the standard treatment regimen33. Hedgehog (Hh) and NOTCH are other pertinent pathways that are vital for LSCs’ latency and survival dysregulation, significantly affecting myeloid differentiation and disease progression31. FLT3-ITD, GATA2, CEBPA, and RUNX1 genetic mutations also played crucial roles in the stemness and resistance of LSCs. For instance, FLT3-ITD mutations enhance the anti-apoptotic MCL1 through STAT5 signaling, and mutations in GATA2, CEBPA, and RUNX1 augment self-renewal and differentiation blockades, allowing LSC to remain thriving even after aggressive treatment regimens34–36. Other immunosuppressive mechanisms LSCs exhibited high levels of CD47, and a “don’t eat me” signal that renders them resistant to phagocytosis by macrophages37. Overexpression of CD47 is also implicated in the persistence of minimal residual disease and resistance to chemotherapy, making it an appealing target for novel immune-based interventions38. AML LSCs are also capable of generating immunosuppressive factors, such as galectin-1 and CD200, which can dampen the inflammatory response and facilitate immune evasion39,40. Notably, AML-intrinsic and stromal/immunosuppressive cell-mediated pathways synergize to maintain immune escape41,42. Nature-killer cell surveillance escape is another mechanism of immune evasion that has been found to reduce the immune recognition and lysis of NK cells. AML myeloid progenitor cells achieve this through several mechanisms, including downregulation or epigenetic silencing of ligands that trigger NK cell-induced cell death, augmenting the expression of inhibitory receptors on the NK cells, and production of immunosuppressive molecules that lower NK cell activity. LSCs are primarily immune-privileged; normally, they are devoid of NK-activating cues such as NKG2D ligands and CD48, resulting in evasion from innate immune surveillance43. These multi-factorial escape mechanistic pathways are responsible for AML’s insensitivity to immunotherapeutic strategies that have revolutionized the treatment of tumors, like immune checkpoint inhibitors. Subsequently, T and NK cell activities are functionally inactivated; newer modalities must be used, such as the combinatorial approach of immune-checkpoint inhibitors with epigenetic agents or microenvironment-targeted drugs to disrupt the extensively maintained immune-favored sanctuary of AML cells. Influence of microenvironment and niche remodeling The bone marrow microenvironment (BMM), often referred to as the bone marrow niche, is the central hub of hematopoiesis and plays a vital role in both hematopoiesis and leukemogenesis. Following AML cell infection, malignant BMM formation occurs, rendering LSCs protected from chemotherapy-mediated cytotoxicity22. AML leukemic blast cell performs extensive remodeling of the bone-marrow niche, endothelial cells, and mesenchymal stem cells altogether creating a supportive microenvironment by enhancing the upregulation of adhesion molecules (P- and E- selectins, ICAM-1, and VCAM-1) and altering the cytokine secretion (IL-3, IL-6, G-CSF, GM-CSF, Nitric oxide) that encourages leukemic homing, adhesion and proliferation44,45. MSC-derived endothelial cells are associated with accelerated disease progression, as they create a safe haven through adhesion and paracrine interactions44. Adrenergic fibers of the autonomic nervous system regulate the MSC niche environment in the bone marrow, which controls MSC niche activity; their inhibition disrupts normal hematopoiesis but encourages leukemic cell proliferation and survival. AML blast cells engulf niche cellular machinery to induce chemoresistance and elicit a cascade of events termed ‘cellular silence,’ wherein LSC becomes less susceptible to immune and therapeutic attack46. Niche remodeling and LSC modulation together reinforce AML’s resistance and can be considered promising therapeutic targets for assisting in prolonged disease control. Delineation of macrophage crosstalk in AML Macrophages are highly plastic immune cells, phenotypically divided into M1 (proinflammatory) and M2 (anti-inflammatory) states, orchestrating a multidimensional cascade of events from immune surveillance to disease progression12. In AML, TAM (tumor-associated macrophages) have emerged as key regulators of disease progression, leukemic pathophysiology, and bone marrow environment. M1 macrophages secrete cytokines such as IL-12 and TNF-α, and express markers like CD80 and CD86, which induce anti-tumor immunity and elicit cytotoxic effects. They are found to exert an anti-leukemic effect by generating reactive oxygen species (ROS), nitric oxide (NO), and pro-inflammatory cytokines47. M1 macrophages exhibit high expression of αDβ2, leading to adhesion and reduced migration, whereas M2 macrophages induce integrin expression, resulting in enhanced motility and tissue infiltration48. Using integrin-mediated interactions, M2 macrophages home towards leukemic niches to enable direct communication between leukemic blast cells and stromal cells49. Several chemokines, such as CCL2, CCL5, CCL7, CCL16, CCL20, CXCL8, CXCR4, SDF-1 (CXCL12), IL-1β, IL-6, IL-8, IL-17, TGF-β, and TNF, are secreted by leukemic stem cells, which attract M1 macrophages and further polarize them to the M2 phenotype50,51. This incessant supply of TAM enhances leukemic progression and niche remodeling52. M2 macrophages secrete anti-inflammatory cytokines like IL-4, IL-10, IL-13, and TGF-β, and are involved in tissue repair, angiogenesis, and, in the context of malignancy, immune suppression leading to decreased immunological control and cancer eradication12. M2-like TAMs enrich BMM and aid in LSC maintenance, enhance remodeling of bone marrow, and release growth factors and survival cues for leukemic cell survival. M2-like TAMs secrete IL-10, TGF-β, CCL2, and release TAM-derived growth factors such as VEGF and M-CSF (enhanced angiogenesis and monocyte recruitment), hampering cytotoxic T cell activity and enhancing regulatory T cell expansion that facilitates evasion of leukemic cells from the immune system53. Integrin-dependent adhesion molecules like αMβ2 (CD11b/CD18) and αDβ2 regulate macrophage trafficking to bone marrow niches. In AML, M2-like TAM exhibits reduced phagocytic activity, leading to the persistence of leukemic cells. In contrast, M2 and bone marrow resident macrophages suppress leukemic cells through LC3-associated phagocytosis, thereby activating the STING pathway54. Higher M2-like TAM expression is associated with poorer overall survival. The bone marrow niche comprises a distinct osteoblast and perivascular microenvironment, with each region supporting dedicated cell types and functions. During normal hematopoiesis, macrophages interact with HSCs and stromal cells to maintain homeostasis; however, in AML, leukemic cells co-opt these niches and replace normal HSCs, reprogramming their microenvironment to support leukemic cell survival55. Macrophages are essential to this process. AML blast cells reprogram their stromal niches, enabling them to adopt a pro-tumorigenic phenotype that involves cell-cell interactions, including the exchange of soluble factors such as cytokines, chemokines, and exosomes. The resulting niche not only supports the survival of leukemic cells but also contributes to therapy resistance by creating a protective sanctuary for LSCs12. Allogeneic hematopoietic stem cell transplantation Allogenic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone curative therapy for AML patients. Although an array of new therapeutic modalities has emerged for the management of AML, allo-HSCT remains an effective and realistic treatment option, and in some cases, it is the only curative modality for intermediate- and adverse-risk AML patients56. Despite achieving complete remission after personalized induction therapy, the risk of relapse hovers significantly in the majority of patients after the first complete remission, and allo-HSCT has been instrumental in efficiently preventing the recurrence of disease compared to standard post-remission57. It has also been observed that approximately 40% of patients with refractory/ relapses of disease failed to achieve complete remission58. The transplant outcome has improved significantly with a better understanding of donor selection, the adoption of prophylactic measures and approaches to prevent GVHD, and post-transplant compliance strategies to increase the relevance of this curative therapy56. Allo-HSCT combines the therapeutic efficacy of myeloablative regimens and cytotoxic conditioning with the GVL effect to eradicate residual leukemic cells. The determining factors in allo-HSCT’s efficacy are myeloablation conditioning and the GVL effect, both modulated by immune cells59. Human Leukocyte antigen (HLA) matching between the donor and recipient minimizes GVHD, preserves residual alloreactivity against leukemic cells, and is considered a significant factor for complete remission. Patients with mild chronic GVHD who undergo post-transplant donor lymphocyte infusion highlight the effectiveness of GVL in AML management60. The application of allo-HSCT is not limited to related haploidentical, younger, fit siblings; it has also been extended to unrelated haploidentical and older patients61. Even though allo-HSCT possesses immense curative potential, it carries grave risk in the form of off-target organ toxicities, risk of developing acute and chronic GVHD, and other associated toxicities. Over time, survival benefits (from treatment-associated mortality) have been shown to improve with appropriate donor selection, graft modulation, and the use of advanced conditioning regimens. State-of-the-art research is centered on mitigating risk stratification, enhancing the GVL effect while minimizing GVHD, and optimizing the conditioning regimen pre- and post-transplant62. Essentially, allo-HSCT serves as a curative therapy for AML patients, demonstrating effective anti-leukemic potential and the likelihood of durable remission in highly vulnerable patients. Improvements and advancements in transplant procedures, with better understanding of donors and recipient selections, have demonstrated increased survival outcomes across a wide range of AML patients. Immune checkpoint signaling and its inhibitors Innate immune checkpoint (ICIs) signaling regulates antitumor response, is involved in direct signaling of AML blasts and LSCs driving differentiation, expansion, and renewal of leukemic cells, and is partially responsible for disease relapses63. ICIs comprise an array of cell surface proteins, glycans, receptors, and ligands that regulate B and T-cell activation, belonging to two major superfamilies: the tumor necrosis factor receptor superfamily (TNFRSF) and the immunoglobulin superfamily (IgSF)64. Adaptive immune systems, signaling pathways interfering with the ICIs and their pathways have so far demonstrated limited impact in AML, possibly due to a lower mutational burden and impaired DNA mismatch repair function compared to solid tumors. However, their effectiveness has been improved when combined with chemotherapeutics and hypomethylating agents, leading to upregulation of immune checkpoints on leukemic and immune cells and enhancing tumor antigen presentation. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1) were the first immune checkpoint molecules targeted for cancer treatment in the clinic65. Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4 inhibition) CTLA-4 is a protein expressed on the surface of T-cells that acts to inhibit T-cell differentiation and maturation and suppresses their function66. The costimulatory molecule CD28 helps stimulate T-cell activation, but this process can be blocked if CTLA-4 interacts with its ligands, CD80 and CD86, thereby blocking the stimulatory signals and inhibiting T-cell activity, which can lead to T-cell anergy. This, in turn, may result in high relapses and a poor prognosis65. Recent investigations have emphasized the potential of CTL4-A inhibition as a promising strategy, but warrant further exploration. Ipilimumab was the first FDA-approved IgG1 kappa monoclonal antibody targeting CTLA-4 for the treatment of melanoma, and it has also been used in treating renal cell carcinoma and colorectal cancer. Ipilimumab alone has shown modest clinical efficacy in patients with relapsed/refractory AML undergoing allogeneic HSCT, while a few phase I/II trials combining ipilimumab with decitabine in patients with relapsed, refractory, or untreated secondary MDS/AML have shown a promising safety and efficacy profile67. Programmed Death-Ligand 1 (PD-1/PD-L1) inhibitors Programmed Death 1 (PD-1), an inhibitory checkpoint receptor, is regulated by intracellular immunoreceptor tyrosine-based switch motif (ITSM) and immunoreceptor tyrosine-based inhibitory domain and is highly expressed on the surface of activated T-cells, B-cells, APCs, and NK cells68. PD-1/PD-L1 pathway recruits SHP-2 phosphatase to inhibit T-cell activation and induce dampening TCR and CD28 co-stimulatory signals69. Co-signaling molecules are essential for T-cell receptor-mediated activation; however, many tumor cells, including AML, express PD-L1 that binds with PD1 receptor to suppress effector T-cell functions, leading to T cell apoptosis and facilitating immune evasion by tumor cells. The inhibition of PD-L1 pathways results in the resuscitation of exhausted T cells, thereby restoring antitumor immunity70. Several investigations demonstrated that high PD-L1 expression in AML cases corresponds to poor prognosis and high disease relapse. Several PD-L1 inhibitors, such as Nivolumab, Durvalumab, Pembrolizumab, and Avelumab, have progressed through clinical trials. Similar to CTLA-4 inhibition, these inhibitors have been prescribed in combination with hypomethylating agents or conventional chemotherapy to enhance their efficacy71. Table 1 contains differentiation therapies, chemotherapy, and oligonucleotide-based therapeutic modalities. Nivolumab and Pembrolizumab are IgG4 anti-PD-L1 monoclonal antibodies initially approved for the treatment of metastatic melanoma and some forms of lymphoma, and the combination of nivolumab with BCL-2 inhibitor venetoclax and decitabine (DAC/VEN therapy), as well as the pembrolizumab combination with azacitidine or decitabine, showed promising efficacy in patients with refractory/relapsed AML72,73,74,75. Durvalumab and Avelumab, also PD-L1 inhibitors, have been investigated for their anti-tumor effects in AML in combination with azacitidine76,77. TIM-3 overexpression has been observed in various immune and leukemic stem cells, which correlate with poor outcomes in AML. Sabatolimab (MBG435), a TIM-3 inhibitor, showed excellent safety and efficacy in combination with HMAs in HR-MDS, newly diagnosed AML patients, and in poor-risk genetic subtypes78. Mechanistically, TIM-3’s ligand, galectin-9, forms an autocrine loop and induces apoptosis in TIM-3 + T cells and type 1 T helper cells, leading to immune exhaustion that promotes the self-renewal of leukemic cells, whereas TIM-3 inhibition demonstrated excellent efficacy in vivo in reducing leukemic burden in mouse models79. CC-90002 and Hu5F9-G4, which are CD47-SIRPα (signal-regulatory protein alpha) inhibitors, were evaluated in relapsed/refractory AML80. A few emerging ICIs, such as ICOS, an inducer of regulatory T cell (Treg) activation, and NKG2A, have been introduced lately to improve the prospects of immune-based therapies, but their clinical investigations are yet to be carried out81. Antibody-based therapies Antibody-based therapies induce cytotoxicity in leukemic cells by employing a monoclonal antibody that utilizes the Fc region to bind immune effectors, thereby triggering NK cell-mediated antibody-dependent cellular toxicity, antibody-dependent cell phagocytosis, and complement-dependent cellular toxicity. Bispecific antibodies simultaneously bind to two antigens on target cells, and antibody-drug conjugates are linked to therapeutic drugs to deliver them to targeted, site-specific locations82. Monoclonal antibodies Monoclonal antibodies target surface antigens (CD123, CD33, TIM-3, CLL-1, CD38, CD56, CD30, CD7, CD47, CD25, CD244, and FLT-3) that are ubiquitously expressed on leukemic AML cells during diagnosis and/or relapsed state, irrespective of genetic characteristics83. Monoclonal antibody treatment regimens include Lintuzumab (CD33), Talacotuzumab (CD123), Cusatuzumab (CD70), and antibody-conjugated toxins such as Gemtuzumab ozogamicin (CD33). Lintuzumab and Talacotuzumab were associated with incomplete remission and limited overall survival benefits in relapsed or refractory AML, whereas Cusatuzumab, a TNF superfamily co-stimulation receptor CD27, demonstrated a marked decrease in leukemic stem cells in early clinical trials. It was also observed that Cusatuzumab modulated the expression of nine genes (FOS, FOSB, DUSP1, JUN, KFL6, CH17-373J23.1, PPP1R15A, LINC000936, and AC090498) that regulate myeloid differentiation and cell death84. Bispecific antibodies Recent developments have led to the emergence of several distinct types of bispecific antibodies, including bispecific T-cell engagers (BITEs), bispecific killer-cell engagers (BIKEs), trispecific killer-cell engagers (Trikes), tandem diabodies (TanAbs), and dial affinity retargeted antibodies (DARTs)85. BiTEs and BiKes selectively target leukemia-associated antigens like CD33, simultaneously engaging with immune effector cell markers and successfully sparing HSCs85. Bispecific antibodies enable simultaneous binding to target cells and immune effector cells, triggering a robust and sustained immune response that facilitates the formation of immune memory85. LAVA-051 is a novel bispecific antibody, also referred to as a gamma-delta T-cell engager (humanized Gammabody), that stimulates both Vγ9Vδ2 and T-cells, as well as type 1 NKT cells (natural killer T-cells), to kill CD1d-expressing cancerous cells. MGD024 is an investigational CD123 × CD3 bispecific antibody that binds to CD3 on immune effector T cells, enabling the destruction of CD123-expressing malignant cells. It has also shown a promising safety and efficacy profile in patients with relapsed or refractory disease. XmAb18968, an engineered CD38-CD3 bispecific T-cell engager, simultaneously binds to CD3 on T cells and CD38 expressed on tumor cells, thereby activating cytotoxic T lymphocytes to eradicate CD38-positive tumor cells86. AMG330 is a prototypic BiTEs designed to target CD33 on leukemia cells and CD3Ԑ on T cells and has shown a modest clinical response in some patients, including complete remissions and anti-leukemic effect87. Vibecotamab is a bispecific antibody that targets CD123-positive cells and has shown a promising anti-leukemic response in patients with relapsed or refractory AML with optimal safety and tolerability88. Trispecific antibodies Trispecific antibodies (TsAbs), also known as trispecific T-cell engagers/trispecific killer-engagers (TriKES), selectively target three different antigenic epitopes on tumor cells and immune effector cells89. TsAbs aim to augment the immune response against leukemic AML cells and enhance tumor-cell specificity, thereby limiting the prospect of tumor escape and fostering maximum therapeutic efficacy. CD16 × CD123 × CD3390, CD16 × CD33 × CD12391 and CD38/CD28xCD392 have demonstrated extraordinary efficacy in both preclinical and clinical investigations. Antibody-drug conjugates (ADCs) Antibody-drug conjugates (ADCs)are a newer class of immunotherapy that combines the advantage of highly specific targeted cytotoxicity with high accuracy and reduced off-target toxicities in hematological malignancies like AML93,94. ADCs primarily consist of a monoclonal antibody, a cytotoxic payload, and a linker molecule95. Each of the units performs a selective function, such as a monoclonal antibody, which allows for the selective binding to surface antigens like CD123, CD33, FLT-3, and CLL-1 that are overexpressed on leukemic stem cells96. While the linker molecule acts as a coupling agent that bridges the antibody with the cytotoxic drug, it is intended to limit the premature release of the drug payload in plasma, resulting in active and controlled drug release profiles at the anticipated target site94,97. The ADC attaches to surface antigens, glides into the lysosome via receptor-mediated endocytosis, where the linker is cleaved to release the cytotoxic agent. Certain ADCs are capable of delivering a “bystander effect,” in which payloads with membrane-permeable features diffuse into the surrounding tumor cells and prolong the effect98. An optimal ADC target should be overexpressed in AML cells with limited/ negligible expression in normal cells, leading to reduced off-target toxicity. CD33 and CD123 are the prime candidates with increasing interest in CD47, FLT-3, and CLL-199. Several ADCs have been combined with targeted therapies/chemotherapeutic agents to enhance their efficacy. Ongoing clinical trials are evaluating the combination of ADCs with hypomethylating agents, FLT3 inhibitors, and checkpoint inhibitors to enhance the killing of leukemic cells and circumvent resistance to these treatments. Some of the combinations are described below: Gemtuzumab-Ozogamicin (GO) is the first ADC approved by the FDA for the treatment of AML (CD33+) in humans, but was subsequently withdrawn from the market due to toxicity. Later on, it was relabeled and recommended for adult treatment of newly diagnosed patients with CD33+ AML in relapse cases, utilizing a different, less toxic dosing schedule100. BL-M11D1 is a novel CD33-targeting second-generation ADC combined with a topoisomerase I inhibitor, aiming to enhance efficacy and stability. It is mainly intended to be used for the evaluation of relapsed/refractory AML cases101. Debio 1562 M is a CD37-targeted ADC that is currently undergoing Phase 1/2 clinical trials to assess its safety and anti-leukemic effects. It targets CD33/CD123 to tackle resistance and antigen heterogeneity. S227928 is a CD74-targeted ADC undergoing phase ½ clinical trials against relapsed/ refractory AML cases and aims to evaluate safety, tolerability, and anti-leukemic response as a single agent and in combination with venetoclax. FLT-3-targeted ADCs are 20D9h3 conjugated to duocarmycin (DUBA) and monomethyl auristatin F (MMAF), and have excellent potency to eradicate quiescent LSCs; however, aggregation, stability, and ADMET properties still need to be optimized102. Several other ADCs with multiple agents targeting CD123, CLL-1, and CD47 are also in preclinical and clinical stages of development to overcome single-antigen targeting and resistance103. Advanced ADC emerging therapies include dual-payload ADCs, which utilize lysine-cysteine-mediated conjugation to adjust the drug-antibody ratio, thereby improving overall efficacy, reducing aggregation, and enhancing cytotoxicity potential104. Figure 2 illustrates antibody-based and cell-based targeted therapies for tackling mutational resistance and LSCs cross-talk in AML.Fig. 2Schematic depiction of immune cell-interactions with AML blast cells and targeted immunotherapies for tackling mutational resistance and LSCs crosstalk in AML.All the receptors, ligands, effectors and soluble factors are directly labeled to their corresponding cells with background (blue color) signifying the heterogeneous leukemic environment consisting of T-cell (green) NK-cell (spiked, purple-colored cells), IFN-γ (blue spheres), IL12 (yellow spheres), IL-2 (gray spheres), chemokines (multicolored spheres), dendritic cells and AML blast cells. The figure depicts multifactorial antileukemic responses, highlighting natural immune surveillance pathways comprising T-cell- and NK-cell-based therapies, immune checkpoint blockade (PD-1/PD-L1 and CTLA-4), macrophage-targeted CD47-SIRPα inhibition, macrophage phagocytosis, bispecific/trispecific engagers, and CAR-engineered effector cells. Schematic depiction of immune cell-interactions with AML blast cells and targeted immunotherapies for tackling mutational resistance and LSCs crosstalk in AML. All the receptors, ligands, effectors and soluble factors are directly labeled to their corresponding cells with background (blue color) signifying the heterogeneous leukemic environment consisting of T-cell (green) NK-cell (spiked, purple-colored cells), IFN-γ (blue spheres), IL12 (yellow spheres), IL-2 (gray spheres), chemokines (multicolored spheres), dendritic cells and AML blast cells. The figure depicts multifactorial antileukemic responses, highlighting natural immune surveillance pathways comprising T-cell- and NK-cell-based therapies, immune checkpoint blockade (PD-1/PD-L1 and CTLA-4), macrophage-targeted CD47-SIRPα inhibition, macrophage phagocytosis, bispecific/trispecific engagers, and CAR-engineered effector cells. Vaccines The current AML treatment approach of consolidated HSCT can fail to clear MRD (minimal residual disease), and disease relapses due to therapy-resistant LSCs21. The advent of an AML vaccine is turning out promising and shows significant potential in preventing disease relapse, especially in patients who are unable to tolerate intensive therapies21. Recently, several vaccine candidates have advanced to clinical trials, demonstrating promising prospects for safe, effective, and durable AML therapy. Peptide-based vaccines, dendritic cell vaccines, and neo-antigen platforms have been introduced lately to stimulate the immune system and selectively target and eradicate LSCs and MRD105. Peptide-based vaccines To elicit an effective immunogenic response, tumor-associated antigens (TAA) or leukemia-associated antigens (LAA) can be used to formulate peptide vaccines. A suitable LAA is rendered target-specific, highly immunogenic, non-toxic, and critically restricted to leukemic cells/niche106. The effectiveness of peptide vaccines depends on several factors, including peptide affinity, peptide length, the antigenicity of adjuvants, and the activation of antigen-presenting cells. Notable LAA targets of peptide vaccines are: Wilm’s tumor antigen (WT-1), hyaluronic acid-mediated motility (RHAMM), mucin-1 (MUC1), and proteinase-3107. WT-1 is responsible for regulating zinc-finger transcription factors that affect cellular growth and differentiation. WT-1 vaccines have been considered safe and effective. In recent phase III clinical trials, they showed complete remission in 64% of patients characterized by increased CD4+, CD8+, and IFN-γ secretion108. RHAMM is a cell surface receptor involved in the generation of cell-cycle proteins that aid in cellular migration and microtubular stability, and is highly expressed in nearly 80% of AML cases. RHAMM-derived CD8 + T cell epitope can elicit cytotoxic T-cell response against myeloid blast. In a Phase I/II clinical trial investigation, 70% of patients showed a positive clinical and immunological response when administered the RHAMM-R3 peptide vaccine. In an independent investigation, nine patients were administered a high dose (1000 µg) of RHAMM-R3 peptide vaccine subcutaneously, without major drug-induced adverse events109. One of the peptide vaccines, AML-VAC-XS15, includes a few peptides derived from AML-associated mutations (NPM1, IDH2) and leukemia stem cell antigens. In ongoing phase I/II clinical trials, AML-VAC-XS15 has been able to stimulate robust, leukemia-specific T-cell responses with promising early safety and immunogenicity profiles. AML-VAC-XS15 has been formulated as a remission-maintenance treatment for patients to prevent MRD-driven relapses by eliminating residual cancerous cells110. Dendritic cell vaccines Dendritic cells (DCs) are specialized, key antigen-presenting cells that orchestrate immune responses and are often referred to as “conductors,” bridging adaptive and innate immunity111. DC vaccines mainly rely on patients’ own dendritic cells that are pulsed ex vivo together with AML antigens like WT1 (Wilms’ tumor protein), PRAME (proteinase 3, preferentially expressed antigen in melanoma), hTERT (human telomerase reverse transcriptase), RHAMM/CD168 (receptor for hyaluronic acid-mediated motility), and Survivin112. These vaccines aim to induce a strong cellular immunogenic response and demonstrate promising clinical outcomes resulting in partial/complete remissions in phase I/II clinical trials113. DCleu (Leukemia-derived dendritic cells), mo-DCs (monocyte-derived dendritic cells), and hybridomas are a few primary vaccination strategies employed to curb the MRD and prevent leukemia relapse114. Neoantigen vaccination strategies (AML-VAC-XS15-01), tailored for personalized individual patients’ leukemic mutations, are under intensive investigation, although none of them has been approved by the US FDA115. Universal vaccines, such as TriLeukeVax, that target multiple AML antigens are also in the early stages of development and are primarily aimed at geriatric patients with leukemia. CAR-T therapy Chimeric antigen receptor (CAR) T-cell therapy, often referred to as the “living drug,” has emerged as a transformative immunotherapy for hematological malignancies. It employs genetic modifications in patients’ own T-lymphocytes to produce artificial receptors that identify and attack malignant cells116. CARs are recombinant, synthetic, modular receptors engrafted with antigenic specificity on immune effector cells to improve their efficacy. Prototypically, structural components of CARs comprise of (i) an extracellular antigen-binding region (mostly containing single chain variable fragment or scFv derived from monoclonal antibodies) that enables selective binding to antigens such as CD33, CD123, or CLL-1 on AML cells; (ii) the hinge domain is the highly flexible region responsible for facilitating CAR-target antigen engagement and maintains the spatial space between antigen-binding domain and T-cell membrane and prevent steric hindrance; (iii) a transmembrane domain (derived from CD28 or CD8α) responsible for anchorage of CAR construct in the T-cell membrane and influences the signaling and stability of CAR; (iv) an intracellular signaling domain that includes CD3ζ activation domain and an additional costimulatory domain such as CD28 or 4-1 BB that collectively triggers proliferation and activation of T-cell, and effector functions117,118. CAR-T cell therapy triggers a multifaceted cascade of cellular and molecular events, encompassing antigen recognition, the formation of memory cells, and the elimination of the target cell. The mechanism of action is initiated by the binding of the CAR to target antigens presented on the surface of cancer cells, triggering T-cell activation through CD3ζ-dependent signaling and co-stimulatory receptors, such as CD28 or 4-1BB. Furthermore, activated CAR-T cells undergo extensive proliferation and destroy cancerous cells through various mechanisms, including perforin- and granzyme-mediated cytotoxicity, Fas-FasL-induced apoptosis, and the release of pro-inflammatory cytokines. It renders a “living drug” response effect that persists in the patient’s circulatory system, delivering constant anti-tumor surveillance119. Clinical trials targeting AML with LeY, CD38, CD123, CLL-1, or IL-1RAP antigen receptors have shown excellent efficacy; however, no FDA-approved CAR-T therapies are currently available. However, six FDA-approved CAR-T cell-based FDA approved products, which are being used to treat B-cell malignancies, are as follows: KYMRIAHTM (Tisagenlecleucel), YESCARTATM (Axicabtagene Ciloleucel), and BREYANZI® (Lisocabtagene maraleucel) for patients with r/r large B-cell lymphoma, TECARTUSTM (Brexucabtagene Autoleucel) for r/r patients with mantle cell lymphoma, ABECMA® (Idecabtagene Vicleucel) and CARVYKTITM (Ciltacabtagene Autoleucel) for patients with r/r multiple myeloma120. These therapies primarily target CD19 or BCMA antigens (which are absent on myeloid cells), underscoring the exceptional intricacy in designing and developing an effective CAR-T therapy for AML. The newer generations of CAR, antibody-based, and cell-based therapeutic modalities are shown in Table 2.Table 2Newer generations of antibody-based and cell-based therapeutic modalitiesImmunotherapyModalityTargetTrial StageAntibody-based therapyNivolumabmABPD-1Phase 1/2PembrolizumabmABPD-1Phase 2MagrolimabmABCD47Phase1/2/3SabatolimabmABTIM-3Phase 1/2TiragolumabmABTIGITEarlyVibostolimabmABTIGITEarlyEgistilimabmABTIGITEarlyCobolimabmABLAG-3Phase2/3RelatlimabmABLAG-3Phase2/3TebotelimabBsAB-DARTPD-1×LAG-3Phase 1/2Gemtuzumab-ozogamicinADCCD33FDA ApprovedFlotetuzumabBsABCD123×CD3Phase 1/2VibecotamabBsABCD123×CD3Phase 1/2AMG 330BiTECD33×CD3Phase 1AMV 564BsABCD33×CD3Phase 1CAR-NKLAVA-051GammabodyCD1dPhase 1AFM28IgG-ROCKIL-3Rα/CD123Phase 1CC-96191/DF2001TriNKETCD33Phase 1CC-92328/DF3001TriNKETCD16Phase 1IPH6401/SAR445514ANKETCD16Phase 1/2IPH6101/SAR443579ANKETCD123Phase 1/2GTB-3650TriKEIL-15/CD33Phase 1CAR-TT-cellCLL1Phase 1/2MB-102T-cellCD123Phase 1UniCAR02-T-CD123T-cellCD123Phase 1UCART123v1.2T-cellCD123Phase 1CD123-CAR-TT-cellCD123Phase 1CD33-CAR-TT-cellCD33Phase 1PRGN-3006T-cellCD33Phase 1CLL1-CD33 cCAR-TT-cellCD33×CLL1Phase 1POC-SMCT-cellCD19Phase 1/2RD13-01T-cellCD7Phase 1Anti-CD7 CAR-TT-cellCD7Phase 1CART-38T-cellCD38Phase 1/2CYAD-01 / CM-CS1T-cellNKG2D-LPhase 1NKR-2T-cellNKG2D-LPhase 1/2CYAD-02T-cellNKG2D-LPhase 1Anti-LeY CAR-TT-cellLeYPhase 1 Table 2Newer generations of antibody-based and cell-based therapeutic modalitiesImmunotherapyModalityTargetTrial StageAntibody-based therapyNivolumabmABPD-1Phase 1/2PembrolizumabmABPD-1Phase 2MagrolimabmABCD47Phase1/2/3SabatolimabmABTIM-3Phase 1/2TiragolumabmABTIGITEarlyVibostolimabmABTIGITEarlyEgistilimabmABTIGITEarlyCobolimabmABLAG-3Phase2/3RelatlimabmABLAG-3Phase2/3TebotelimabBsAB-DARTPD-1×LAG-3Phase 1/2Gemtuzumab-ozogamicinADCCD33FDA ApprovedFlotetuzumabBsABCD123×CD3Phase 1/2VibecotamabBsABCD123×CD3Phase 1/2AMG 330BiTECD33×CD3Phase 1AMV 564BsABCD33×CD3Phase 1CAR-NKLAVA-051GammabodyCD1dPhase 1AFM28IgG-ROCKIL-3Rα/CD123Phase 1CC-96191/DF2001TriNKETCD33Phase 1CC-92328/DF3001TriNKETCD16Phase 1IPH6401/SAR445514ANKETCD16Phase 1/2IPH6101/SAR443579ANKETCD123Phase 1/2GTB-3650TriKEIL-15/CD33Phase 1CAR-TT-cellCLL1Phase 1/2MB-102T-cellCD123Phase 1UniCAR02-T-CD123T-cellCD123Phase 1UCART123v1.2T-cellCD123Phase 1CD123-CAR-TT-cellCD123Phase 1CD33-CAR-TT-cellCD33Phase 1PRGN-3006T-cellCD33Phase 1CLL1-CD33 cCAR-TT-cellCD33×CLL1Phase 1POC-SMCT-cellCD19Phase 1/2RD13-01T-cellCD7Phase 1Anti-CD7 CAR-TT-cellCD7Phase 1CART-38T-cellCD38Phase 1/2CYAD-01 / CM-CS1T-cellNKG2D-LPhase 1NKR-2T-cellNKG2D-LPhase 1/2CYAD-02T-cellNKG2D-LPhase 1Anti-LeY CAR-TT-cellLeYPhase 1 Newer generations of antibody-based and cell-based therapeutic modalities The success of CAR-T therapy in AML is limited by the absence of an ideal target, the presence of immunosuppressive cytokines, an immunosuppressive leukemic niche, regulatory T cells (Tregs) that impede CAR-T cell activity, and myelosuppression121. An effective CAR-T cell therapy is required to overcome these inhibitory cues through augmented combinatorial strategies and optimized CAR design. Antigen heterogeneity is a hallmark of AML, characterized by heterogeneous cellular expression, altered maturation, and differentiation of myeloid blast cells122. Tandem CARs and dual targeting approaches, along with sequential CAR infusion, may circumvent this limitation123. Antigen escape is another method of immune evasion characterized by antigen redistribution, epitope masking, lineage switching, trogocytosis-mediated antigen loss, or the downregulation of target antigens by AML cells124. Several strategies have been proposed recently to overcome these limitations by employing bispecific and trispecific antibodies, novel cell-based therapy interventions such as CAR-macrophages and CAR-NK cells, and continuous monitoring of antigen density125,126. Furthermore, next-generation CAR designs (Fig. 3) will incorporate safety switches, dual-targeting capabilities, and enhanced persistence mechanisms, aiming to enable CAR immune effector cells to drive a paradigm shift in curative treatment for allogeneic transplantation in AML patients.Fig. 3Schematic illustrations of structural evolution of CAR (chimeric antigen receptor) designs for the next generation of CAR-T cell therapies.The figure depicts five CAR constructs ingrained in the lipid bilayer membrane (gray). Each generation consists of an extracellular domain called ScFv (single chain variable fragment) composed of variable heavy (green) and light (blue) chains linked with a transmembrane (light green rectangular module) domain and further modified into newer generations to improve the T-cell activation, proliferation, persistence, effector function, and cytokine production. The first generation of CAR comprises of intracellular signaling domain CD3ζ (multi subunits blue structure) renders activation signal upon antigen binding; second generation contains additional costimulatory domain 1 CM1 (Y-shaped orange structure); third generation incorporates CD3ζ, CM1 and costimulatory domain 2 CM2 (Y-shaped light blue structure); fourth generation contains CD3ζ, CM1, CM2 and an inducer domain IL-12 (oval shaped gray structure linked with phosphorylated-blue sphere); and the fifth generation is composed of CD3ζ, CM1, CM2, IL-12 along with activators such as JAK (light green oval structure) and STAT3/5 transcription factors (maroon bars linked through phosphorylated yellow spheres). Schematic illustrations of structural evolution of CAR (chimeric antigen receptor) designs for the next generation of CAR-T cell therapies. The figure depicts five CAR constructs ingrained in the lipid bilayer membrane (gray). Each generation consists of an extracellular domain called ScFv (single chain variable fragment) composed of variable heavy (green) and light (blue) chains linked with a transmembrane (light green rectangular module) domain and further modified into newer generations to improve the T-cell activation, proliferation, persistence, effector function, and cytokine production. The first generation of CAR comprises of intracellular signaling domain CD3ζ (multi subunits blue structure) renders activation signal upon antigen binding; second generation contains additional costimulatory domain 1 CM1 (Y-shaped orange structure); third generation incorporates CD3ζ, CM1 and costimulatory domain 2 CM2 (Y-shaped light blue structure); fourth generation contains CD3ζ, CM1, CM2 and an inducer domain IL-12 (oval shaped gray structure linked with phosphorylated-blue sphere); and the fifth generation is composed of CD3ζ, CM1, CM2, IL-12 along with activators such as JAK (light green oval structure) and STAT3/5 transcription factors (maroon bars linked through phosphorylated yellow spheres). Future therapeutic perspective The landscape of AML immunotherapy is rapidly evolving towards precision-based and combinatorial treatment approaches to circumvent disease heterogeneity, drug resistance, and immune evasion. Cellular therapies, such as CAR-T cells, CAR-NK cells, engineered macrophages (CAR-M), and TCR-engineered lymphocytes, are considered promising modalities for achieving long-term remission. NK cell-based therapy (CAR-NK) also draws attention due to its low-risk associated cytokine-releasing syndrome and graft-versus-host disease, offering an “off-the-shelf” alternative. mRNA vaccination therapy now holds a stronghold in cancer therapy since its inception, and recent investigations show its potential as a transformative therapy for leukemia-associated antigens (CDH23, LRP1, MEFV, MYOF, and SLC9A9) to induce a robust T-cell immune response. Next-generation CAR-T constructs with dual-antigen targeting and engineered CARs with cytokine secretion capabilities are in the developmental stages, aiming to reduce disease relapses and mitigate antigen escape. The application of artificial intelligence to modulate immune responses and optimize delivery strategies, utilizing nano-bioengineering and synthetic biology approaches, may help improve overall survival outcomes.